Boston Scientific Valuation
Is BSX * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BSX * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BSX * (MX$1250.03) is trading above our estimate of fair value (MX$884.86)
Significantly Below Fair Value: BSX * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BSX *?
Other financial metrics that can be useful for relative valuation.
What is BSX *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$110.51b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 8.1x |
Enterprise Value/EBITDA | 31.9x |
PEG Ratio | 3.4x |
Price to Earnings Ratio vs Peers
How does BSX *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 43x | ||
SYK Stryker | 38.5x | 10.5% | US$127.8b |
MDT Medtronic | 29.3x | 12.9% | US$107.9b |
ISRG Intuitive Surgical | 71.6x | 11.6% | US$143.6b |
SHL Siemens Healthineers | 32.6x | 17.3% | €60.1b |
BSX * Boston Scientific | 62.6x | 18.2% | Mex$110.5b |
Price-To-Earnings vs Peers: BSX * is expensive based on its Price-To-Earnings Ratio (62.6x) compared to the peer average (43x).
Price to Earnings Ratio vs Industry
How does BSX *'s PE Ratio compare vs other companies in the Global Medical Equipment Industry?
Price-To-Earnings vs Industry: BSX * is expensive based on its Price-To-Earnings Ratio (62.6x) compared to the Global Medical Equipment industry average (27.9x).
Price to Earnings Ratio vs Fair Ratio
What is BSX *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 62.6x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BSX *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$1,244.03 | Mex$1,359.08 +9.2% | 5.6% | Mex$1,500.25 | Mex$1,166.86 | n/a | 30 |
May ’25 | Mex$1,233.00 | Mex$1,375.07 +11.5% | 5.7% | Mex$1,531.60 | Mex$1,191.25 | n/a | 32 |
Apr ’25 | Mex$1,130.52 | Mex$1,196.57 +5.8% | 5.8% | Mex$1,351.16 | Mex$1,017.54 | n/a | 31 |
Mar ’25 | Mex$1,141.20 | Mex$1,213.26 +6.3% | 6.6% | Mex$1,378.51 | Mex$936.02 | n/a | 30 |
Feb ’25 | Mex$1,050.23 | Mex$1,190.42 +13.3% | 7.5% | Mex$1,384.01 | Mex$939.76 | n/a | 30 |
Jan ’25 | Mex$949.03 | Mex$1,049.47 +10.6% | 7.1% | Mex$1,311.49 | Mex$894.20 | n/a | 30 |
Dec ’24 | Mex$951.90 | Mex$1,029.02 +8.1% | 4.9% | Mex$1,146.84 | Mex$898.64 | n/a | 30 |
Nov ’24 | Mex$930.75 | Mex$1,086.09 +16.7% | 4.8% | Mex$1,213.14 | Mex$950.59 | n/a | 30 |
Oct ’24 | Mex$914.10 | Mex$1,047.84 +14.6% | 4.5% | Mex$1,137.52 | Mex$947.94 | n/a | 30 |
Sep ’24 | n/a | Mex$1,004.03 0% | 3.9% | Mex$1,073.41 | Mex$922.46 | n/a | 30 |
Aug ’24 | n/a | Mex$998.13 0% | 5.8% | Mex$1,071.64 | Mex$753.50 | n/a | 31 |
Jul ’24 | n/a | Mex$995.16 0% | 5.6% | Mex$1,095.65 | Mex$770.38 | n/a | 30 |
Jun ’24 | Mex$893.24 | Mex$1,010.17 +13.1% | 5.5% | Mex$1,088.31 | Mex$789.90 | n/a | 29 |
May ’24 | n/a | Mex$1,020.54 0% | 6.3% | Mex$1,111.57 | Mex$806.79 | Mex$1,233.00 | 27 |
Apr ’24 | n/a | Mex$953.04 0% | 6.2% | Mex$1,063.32 | Mex$811.01 | Mex$1,130.52 | 26 |
Mar ’24 | Mex$844.50 | Mex$994.49 +17.8% | 6.3% | Mex$1,117.30 | Mex$852.18 | Mex$1,141.20 | 27 |
Feb ’24 | n/a | Mex$958.19 0% | 6.0% | Mex$1,042.78 | Mex$837.95 | Mex$1,050.23 | 26 |
Jan ’24 | n/a | Mex$973.17 0% | 5.9% | Mex$1,075.94 | Mex$880.32 | Mex$949.03 | 28 |
Dec ’23 | Mex$870.60 | Mex$944.48 +8.5% | 4.4% | Mex$1,028.93 | Mex$873.62 | Mex$951.90 | 26 |
Nov ’23 | Mex$837.22 | Mex$964.98 +15.3% | 4.9% | Mex$1,051.43 | Mex$892.72 | Mex$930.75 | 26 |
Oct ’23 | Mex$800.26 | Mex$982.24 +22.7% | 5.6% | Mex$1,080.15 | Mex$876.35 | Mex$914.10 | 24 |
Sep ’23 | n/a | Mex$970.71 0% | 5.6% | Mex$1,067.47 | Mex$866.06 | n/a | 24 |
Aug ’23 | n/a | Mex$971.52 0% | 5.5% | Mex$1,076.27 | Mex$873.20 | n/a | 24 |
Jul ’23 | Mex$763.67 | Mex$977.84 +28.0% | 5.9% | Mex$1,087.07 | Mex$865.63 | n/a | 23 |
Jun ’23 | Mex$790.76 | Mex$974.73 +23.3% | 5.2% | Mex$1,078.04 | Mex$862.43 | Mex$893.24 | 24 |
May ’23 | Mex$876.00 | Mex$1,025.96 +17.1% | 4.9% | Mex$1,122.48 | Mex$918.39 | n/a | 24 |
Analyst Forecast: Target price is less than 20% higher than the current share price.